Reports assess risk and benefit of list of medicines
ANVISA has announced the availability of the list of medicines that Drug Registration Holders (DRMs) must submit Periodic Benefit-Risk Assessment Reports (RPBRs) for by June 30, 2024.
ELS can help from the development to the registration of medicines in Brazil, Latin America and Europe.
ontact your local ELS consultant or via email info@elssolutions.pt
ELS Group brings together a team of highly specialized professionals with proven experience in regulatory frameworks and compliance in the pharmaceutical field.
Rely on experts to support your regulatory decisions and accelerate the growth of your products safely and efficiently.
Experts in pharmaceutical consulting, regulatory strategy, and market access to support your company with safety, compliance, and efficiency. Talk to a consultant.
